Oxford BioMedica plc · LSE:OXB
Oxford BioMedica — FY2017 Earnings Presentation
19 slides from Oxford BioMedica's earnings presentation, Mar 15, 2018
Slide 1: Gene Therapy Is Now: Preliminary results for the year ended 31 December 2017
GENE THERAPY IS NOW Preliminary results for the year ended 31 December 2017 15 March 2018
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the “Securities”). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed 2 Cohort
Slide 3: 2017 Operational Highlights
2017 Operational Highlights1 • LentiVector® delivery platform • Major commercial supply agreement with Novartis worth potentially > $100m over three years Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 • $5 million 1x upfront andOriginal Mean 27%
Slide 4: Strategy: Leveraging our delivery platform
Strategy: Leveraging our delivery platform LentiVector® Platform IP – patents and know-how | Facilities | Expertise | Quality systems Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max
Slide 5: Novartis CAR-T partnership
Novartis CAR-T partnership Novartis partnership in place since 2014, with new agreement 2 Cohort inDose 2017 Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Forbes (26 May 2014) 1, n=3 1x Original Mean 27% Mean 30% 29% MeanJoe Jimenez said: Mean 20% Max. up to 30% Max
Slide 6: Bioverativ haemophilia partnership
Bioverativ haemophilia partnership Bioverativ partnership agreement signed in Feb-18 Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Mean 27% Mean 30% Mean 29% Mean 20% John G. Cox, CEO Bioverativ said: 1,Product n=3 development 1x Factor OriginalVIII and
Slide 7: Extensive lentiviral vector clinical/pre-clinical trial activity
Extensive lentiviral vector clinical/pre-clinical trial activity New York Times, Gina Kolata Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year(27 (UPDRS) 2 years (UPDRS) November 2017) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% "Few Max. u
Slide 8: Product pipeline
Product pipeline Product Indication Pre-Clinical Phase I Phase I/II Phase II Phase III Approval LentiVector® platform CTL0191,2 r/r ALL Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) CTL0191 r/r DLBCL 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20
Slide 9: Financial review
Financial review
Slide 10: 2017 Financial Highlights
2017 Financial Highlights • 28% increase in gross income1 to £39.4m (2016: £30.8m) • 12% decrease in operating expenses2 to £22.9m (2016: £26.1m) Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. u
Slide 11: Gross income and EBIDA
Gross income1 and EBIDA2 Gross income (£m) Gross income (£m) 50 50 40 Cohort2 Dose Administration 40 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) Licences, 2 years (UPDRS) incentives, 1,30 n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Other Max. up to 30% 30 Includes Max. up to 50%£6.1m Ma
Slide 12: Segmental analysis
Segmental analysis Platform segment (£m) Product segment (£m) 2016 2017 2016 2017 45 Cohort2 Dose Administration 3 months (UPDRS) 2 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 40 1, n=3 1x Original Mean 27% 1 Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30%
Slide 13: Market for lentiviral vector development & bioprocessing
Market for lentiviral vector development & bioprocessing • The Company estimates the lentiviral vector bioprocessing market was worth around $200m in 2017 and will Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) Mean 27% Mean 30% Mean 29% Mean 20% grow to
Slide 14: Expansion plans and fundraise
Expansion plans and fundraise • Oxford BioMedica has identified premises to lease in Oxford close to its existing headquarters that are suitable for a new bioprocessing facility that will 2 Cohort include: Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x
Slide 15: 2018 Financial outlook
2018 Financial outlook • Expect gross income to continue to grow strongly • 3 GMP suites and laboratories fully operational Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) • Multiple revenue generating partners with potential for further new partnerships
Slide 16: Summary
Summary
Slide 17: Expected news flow
Expected news flow Partners’ programmes Novartis Cohort2 2nd CAR-T Royalty stream from Expected approval for Expected EMA approval for Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% programme to Novartis/CTL
Slide 18: Summary: World leading gene and cell therapy company
Summary: World leading gene and cell therapy company Cohort2 Dose Administration 3 months (UPDRS) 6 months (UPDRS) 1 year (UPDRS) 2 years (UPDRS) 1, n=3 1x Original Mean 27% Mean 30% Mean 29% Mean 20% Max. up to 30% Max. up to 50% Max. up to 44% Max. up to 30% 2, n=3 2x Original Mean 28% Mean 34% Me
Slide 19: Contact Us
Contact Us Oxford BioMedica plc Windrush Court Transport Way Oxford OX4 6LT John Dawson, CEO Stuart Paynter, CFO Tel: +44 (0) 1865 783 000 enquiries@oxfordbiomedica.co.uk www.oxfordbiomedica.co.uk